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RESEARCH ARTICLE Open Access
MiR-193b promotes autophagy and non-
apoptotic cell death in oesophageal cancer
cells
Michelle J. Nyhan1, Tracey R. O’Donovan1, Antonius W. M. Boersma2, Erik A. C. Wiemer2 and Sharon L. McKenna1*
Abstract
Background: Successful treatment of oesophageal cancer is hampered by recurrent drug resistant disease. We
have previously demonstrated the importance of apoptosis and autophagy for the recovery of oesophageal cancer
cells following drug treatment. When apoptosis (with autophagy) is induced, these cells are chemosensitive and will
not recover following chemotherapy treatment. In contrast, when cancer cells exhibit only autophagy and limited
Type II cell death, they are chemoresistant and recover following drug withdrawal.
Methods: MicroRNA (miRNA) expression profiling of an oesophageal cancer cell line panel was used to identify
miRNAs that were important in the regulation of apoptosis and autophagy. The effects of miRNA overexpression on
cell death mechanisms and recovery were assessed in the chemoresistant (autophagy inducing) KYSE450 oesophageal
cancer cells.
Results: MiR-193b was the most differentially expressed miRNA between the chemosensitive and chemoresistant cell
lines with higher expression in chemosensitive apoptosis inducing cell lines. Colony formation assays showed that
overexpression of miR-193b significantly impedes the ability of KYSE450 cells to recover following 5-fluorouracil (5-FU)
treatment. The critical mRNA targets of miR-193b are unknown but target prediction and siRNA data analysis suggest
that it may mediate some of its effects through stathmin 1 regulation. Apoptosis was not involved in the enhanced
cytotoxicity. Overexpression of miR-193b in these cells induced autophagic flux and non-apoptotic cell death.
Conclusion: These results highlight the importance of miR-193b in determining oesophageal cancer cell viability and
demonstrate an enhancement of chemotoxicity that is independent of apoptosis induction.
Keywords: MiR-193b, Autophagy, Chemosensitivity, Stathmin 1, Oesophageal cancer, Non-apoptotic cell death
Background
Oesophageal cancer is a highly aggressive cancer with a
poor 5-year survival rate (<20 %) [1]. Current treatment
regimens fail to eradicate disseminated tumour cells which
can re-establish as a drug resistant secondary cancer [2].
Our research group previously analysed a panel of
oesophageal cancer cell lines and their response to
treatment with standard chemotherapeutics (5-fluoro-
uracil (5-FU) and cisplatin). Cells that were sensitive to
these drugs were both apoptosis and autophagy compe-
tent and did not recover following withdrawal of the
drug. In contrast, cells that were drug resistant exhib-
ited only autophagy with limited Type II cell death and
recovered following removal of the chemotherapeutics.
Silencing of key autophagy regulators Beclin 1 and
ATG7 verified the crucial role autophagy plays in this
recovery process [3].
Autophagy is an evolutionary conserved catabolic
process in which cells self-digest their own organelles,
protein aggregates and other macromolecules to main-
tain cellular homeostasis. However, when a tumour has
become established, cancer cells utilise autophagy as a
mechanism to protect themselves from adverse stressful
conditions including nutrient starvation, hypoxia and
anticancer treatments [4]. Inducing excessive autophagy
(Type II cell death) has also been identified as an important
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cell death pathway [5]. Autophagy with Type II cell death
has been observed following the treatment of several
different types of cancer with chemotherapeutics [6]. It
is crucial that we have a clearer understanding of the
signalling pathways required to enhance cell death
associated autophagy and prevent autophagy that pro-
motes survival of cancer cells.
The importance of microRNAs (miRNAs) in the regu-
lation of diverse cellular processes implicated in tumour-
igenesis including proliferation, migration, angiogenesis,
metastasis, apoptosis and autophagy has only begun to
emerge. MiRNAs are small, non-coding RNA molecules
of 22–24 nucleotides in length. They act as powerful
negative regulators of gene expression (acting at the
posttranscriptional and translational levels) and are
believed to regulate at least 30 % of human genes. A
single miRNA may target several mRNAs at once and
consequently can act on complex regulatory networks.
Depending on the cellular context and the availability of
direct mRNA targets, the same miRNA may have quite
diverse functions. MiRNAs have now emerged as poten-
tial targets to be exploited for anticancer drug develop-
ment [7–10]. MiRNAs have been identified to have
crucial roles in various stages of autophagy including
induction (e.g. miR-101), vesicle nucleation (e.g. miR-30a),
elongation and completion (e.g. miR-181a), docking and
fusion (e.g. miR-34a) and degradation and recycling
(e.g. miR-17/20/93/106 complex) [11–14]. Several miRNAs
have also been implicated in the development of drug
resistance [15]. However, as this remains an emerging field,
there are likely to be numerous miRNAs, which have yet to
be identified, that regulate cell survival/death mechanisms
and thereby impact on chemosensitivity.
In this study, we present evidence that miR-193b has
an important role in determining the chemosensitivity of
oesophageal cancer cells. Overexpression of miR-193b
significantly reduces the ability of cancer cells to recover
following treatment with 5-FU. MiR-193b may mediate
its effects, at least in part, through decreasing the
expression of stathmin 1. Stathmin 1 is a ubiquitous
cytosolic phosphoprotein that regulates microtubule
dynamics. Its expression levels have previously been
reported to influence the responsiveness of cancer cells
to chemotherapeutics [16–18]. We found that increased
expression of miR-193b does not activate apoptosis but
elevates autophagy and non-apoptotic cell death.
Methods
Cell culture/reagents
Human oesophageal cancer cell lines OE19, OE21 and
OE33 were obtained from the European Collection of
Cell Cultures (96071721, 96062201 and 96070808).
KYSE450 cells were from DSMZ (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, ACC-
387). OE21, OE19 and OE33 cells were grown in RPMI
1640 medium (Sigma, R8758). KYSE450 cells were
maintained in 50: 50 RPMI: F12 HAMS medium
(Sigma, N6658), all supplemented with 10 % foetal calf
serum (Sigma, F7524) and 1 % Penicillin/Streptomycin
(Gibco-BRL, 15070-063) and grown at 37 °C, 5 % CO2.
Chloroquine (C6628) and 5-FU (F6627) were purchased
from Sigma.
Microarray and data analysis
MiRNA expression profiling and data analysis was per-
formed as previously described [19, 20]. The probe set
contained 1344 probes capable of detecting 725 human
miRNAs in addition to mouse, rat and viral probes. These
experiments were carried out in triplicate. The microarray
expression data have been deposited to the Gene Expres-
sion Omnibus (GEO) data repository (accession number
GSE77132).
Real-time PCR
RNA was extracted from all cell lines, cDNA synthesised
and PCR performed as per manufacturer’s instructions
(Qiagen, 217004, 218161 and 218073) using the Lightcycler
system (Roche). MiR-193b (MS00031549) and RNU6B
(used for normalisation; MS00033740) primers were de-
signed and synthesised by Qiagen. Results represent at
least three independent experiments. Expression levels
were quantified using the ‘Delta-Delta’ formula [21].
Transfections
MiR-193b mimics (C-300764-05-0010), scrambled miRNAs
(negative control; CN-001000-01-05), stathmin 1 siRNA
(L-005152-00-0005) and scrambled siRNAs (negative
control; D-001810-01-20) were designed and synthesised
by Dharmacon. Cells were transiently transfected using
Lipofectamine 2000 (Invitrogen, 11668-027) according to
the protocol provided with the reagent. SiGlo green trans-
fection indicator (Dharmacon, D-001630-01-05) was used
to assess transfection efficiency (which was always greater
than 70 %).
Western blotting
Protein extracts were lysed in modified RIPA buffer
(50 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.25 % sodium
deoxycholate, 1 % Igepal, 1 mM EDTA, 1× PefaBloc, 1×
Protease Inhibitor Cocktail, 1 mM Na3VO4, 1 mM NaF).
Protein samples were separated on pre-cast NuPAGE 4–
12 % Bis-Tris gels (Invitrogen, NP0322) and electrophoret-
ically transferred onto PVDF membranes (Invitrogen,
IB401001). Primary antibodies were: anti-stathmin 1
(Abcam, ab52630), anti-LC3 (MBL, PD014) and anti-
actin (Sigma, A5441). Proteins were visualised using
relevant IR-Dye secondary antibodies and quantified
using the Odyssey Infrared imaging system (Li-Cor).
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Colony formation assay
Following treatment, all adherent cells were trypsinised
and counted. Fifteen hundred viable cells were reseeded
in fresh media (without drug) into a well of a six well
plate (in triplicate) and allowed to grow for 10–14 days.
Colonies were then fixed with 96 % ethanol and stained
with ProDiff Solution C (Braidwood Laboratories, 22009).
Plates were scanned using the Odyssey Infrared Imaging
system (Li-Cor) and colonies quantified. Results are
presented as integrated intensity ± standard error of the
mean (SEM) from at least three independent experi-
ments. When colony numbers were very low, colonies
were manually counted.
Flow cytometry assay
Autophagy Cyto-ID Autophagy Detection Kit (Enzo Life
Sciences, ENZ-51031) was used to stain live cells accord-
ing to manufacturer’s instructions. This assay is dependent
on a 488 nm-excitable green fluorescent detection reagent
which specifically fluoresces in autophagic vesicles. An
increase in the 488-2A channel represents an increase in
the number of autophagic vesicles staining green.
Caspase 3 assay Cells were fixed in 4 % paraformaldehyde
and washed in permeabilisation buffer (0.1 % Triton–
X-100, 0.1 % sodium azide, 10 mM HEPES, 4 % FCS,
150 mM NaCl). Subsequently, cells were incubated with
anti-active caspase-3 antibody (BD BioSciences, 559565)
and then with an anti-rabbit FITC conjugated secondary
antibody.
BD-LSRII flow cytometer (BD BioSciences) was used to
detect fluorescence. Data analysis and histogram overlays
were done using the FlowJo software.
Morphological examination of cell death
Following cytospinning onto glass slides, cells were stained
with Pro-Diff (Braidwood Laboratories, 22007, 22008 and
22009). Morphology images were captured using a DP70
digital microscope camera and Olympus DP-Soft823
version 3.2 software. All images are representative of at
least three independent experiments. Apoptosis is identified
by shrinking of the cell, chromatin condensation and DNA
fragmentation into ‘apoptotic bodies’ within an intact
plasma membrane. Type II cell death was characterised by
loss of cytoplasmic material, an increase in the number of
cytoplasmic vesicles, pyknosis (condensed regions) of the
nuclear material and an intact nuclear membrane [22].
HMGB1 ELISA
Following treatment, supernatant was removed from
cells and subsequently diluted 1:1 with dilution buffer.
Measurement of High Mobility Group Box 1 (HMGB1)
concentration was determined using the HMGB1
ELISA kit (Chondrex, 6010) according to manufac-
turer’s instructions.
Statistical analysis
All statistical analysis was performed using GraphPad
Prism version 5. Comparisons between groups were
assessed using Student’s t test.
Results
MiR-193b is differentially expressed between chemosensitive
and chemoresistant oesophageal cancer cells
We undertook miRNA expression profiling of a panel of
oesophageal cancer cell lines which differ in their
response to treatment with chemotherapy drugs. Two of
these cell lines (OE21 & OE33 – Group A) induce apop-
tosis and autophagy and are relatively chemosensitive
and two cell lines (KYSE450 & OE19 – Group B)
respond by inducing autophagy with limited Type II cell
death and have the ability to recover following removal
of cytotoxic drugs [3]. The miRNA expression profile of
Group A versus Group B was analysed on a microarray
platform which consisted of 1344 LNA capture probes,
of which 725 hybridise to annotated human miRNAs. In
this analysis, 440 human miRNAs were expressed above
background level. This screen allowed us to identify
miRNAs which may be have a crucial role in the regula-
tion of these diverse processes.
Supervised clustering analysis (p < 0.005) identified six
miRNAs that were more highly expressed in the apop-
totic chemosensitive cells and two miRNAs that had
higher expression in the autophagy chemoresistant cells
(≥ 1.74-fold change) (listed in Fig. 1a). Of all the miR-
NAs identified in this screen, miR-193b had the greatest
level of differential expression between the two groups
and thus was investigated further. Real-Time PCR con-
firmed that miR-193b was approximately six fold more
highly expressed in the chemosensitive (OE21 & OE33)
cell lines compared to the chemoresistant cell lines
(KYSE450 & OE19) (Fig. 1b).
Overexpression of miR-193b in KYSE450 cells increases
their sensitivity to 5-FU
As miR-193b is more highly expressed in the apoptotic/
chemosensitive cell lines, we evaluated the functional
consequences of miR-193b overexpression (using mimic
technology) in the chemoresistant autophagy inducing
KYSE450 cells. KYSE450 cells were transfected with a
miR-193b mimic or negative control mimic (5 nM) and
treated 24 h later with 5-FU (10 μM or 30 μM) for up to
48 h. Equal numbers of viable cells from each treatment
group were then re-seeded and incubated for up to
12 days in the absence of drug to assess recovery. Overex-
pression of miR-193b was confirmed by examining the
expression levels of stathmin 1. Stathmin 1 is a previously
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validated target of miR-193b (i.e. increased expression of
miR-193b decreases stathmin 1 expression) [23]. Protein
levels of stathmin 1 were reduced in miR-193b mimic
transfected cells compared to negative control cells for up
to 72 h post-transfection (Fig. 2a).
Overexpression of miR-193b mimic alone reduces the
colony re-growth of KYSE450 cells compared to expres-
sion of the negative control mimic (**p = 0.0091). When
miR-193b overexpressing cells were treated with 5-FU
for 24 h, significantly fewer colonies re-grew when com-
pared to 5-FU treated cells expressing the negative
control mimic (***p = 0.0004 and ***p = 0.0007 for 10
and 30 μM 5-FU respectively) (Fig. 2b). A similar pattern
was observed following 48 h treatment (Fig. 2c). Fewer
colonies were observed following miR-193b overexpres-
sion when treated with 30 μM 5-FU for 48 h, but these
differences were below the detection levels of the instru-
ment, therefore these colonies were manually counted
and these data are presented as Fig. 2c (ii). These results
suggest that miR-193b expression can have a significant
impact on viability and chemosensitivity.
MiR-193b may mediate its effect on chemosensitivity
through negative regulation of Stathmin 1
Several of the freely available miRNA target prediction
software programs were used to identify potential targets
of miR-193b. These included Targetscan, Pictar, miRDb,
Targetminer, miRSearch 3.0, Diana-microT, MiRwalk
and MiRTarBase. These programs predicted several
hundred downstream effectors of miR-193b, with a lim-
ited number of genes in common (data not shown).
Stathmin 1 was identified by five prediction software
programs and has been previously reported to be nega-
tively regulated by miR-193b [23, 24]. Functionally, it
has been associated with the destabilisation and disas-
sembly of microtubules [17] and silencing stathmin 1
(using adenovirus technology) in combination with 5-FU
was reported to increase apoptosis and decrease clono-
genic survival of prostate cancer cells [25].
We therefore examined the effects of siRNA knock-
down of stathmin 1 in KYSE450 cells. Western blot
analysis showed that stathmin 1 levels were reduced up
to 72 h following transfection compared to the corre-
sponding scrambled control (Fig. 3a). Reduced clonogenic
survival was observed in KYSE450 cells transfected with
stathmin 1 siRNA and treated with 5-FU for 48 h
compared to the equivalent scrambled siRNA controls
treated with 5-FU (*p = 0.0202, ***p = 0.0009 for 10 and
30 μM 5-FU respectively) (Fig. 3b). A significant difference
was not observed at 24 h (data not shown). Western blot
analysis indicated greater silencing of stathmin 1 at 48 h
which may account for this (Fig. 3a). These results suggest
that knockdown of stathmin 1 can promote sensitivity of
KYSE450 cells to 5-FU. Thus, miR-193b may mediate
some of its effects on chemosensitivity in KYSE450
cells through the negative regulation of the stathmin
1 transcript.
MiR-193b overexpression and 5-FU treatment does not
activate apoptosis
We further investigated the mechanism by which overex-
pression of miR-193b reduces cell viability. We assessed
the levels of both apoptosis and autophagy in transfected
cells. Flow cytometric analysis showed that overexpression
of miR-193b did not increase the levels of active caspase 3
compared to the negative control mimic transfected cells.
There was also no difference following 5-FU treatment for
24 (data not shown) or 48 h (Fig. 4a (i)). This is in contrast
to OE21 cells which showed high levels of active caspase 3
activity following treatment with 30 μM 5-FU for 48 h
(Fig. 4a (ii)). These data suggest that overexpression of
miR-193b in KYSE450 cells does not result in apoptosis
induction and is therefore unlikely to be responsible
for the loss of survival observed in combination with
5-FU treatment.
MiR-193b overexpressing KYSE450 cells treated with
5-FU (10 μM) for 24 h showed a greater accumulation
of vesicles in the cytoplasm when compared to negative
Fig. 1 miRNAs differentially expressed between the chemosensitive and chemoresistant oesophageal cancer cell lines. a The table lists the miRNAs
that are differentially expressed (≥ 1.74-fold) between the chemosensitive (OE21 & OE33) and chemoresistant (KYSE450 & OE19) oesophageal cancer
cell lines. b Real-Time PCR was used to assess the expression levels of miR-193b in these cell lines. RNU6B was used for normalisation and expression
levels were quantified using 2-ΔΔCp
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Fig. 2 (See legend on next page.)
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(See figure on previous page.)
Fig. 2 Examination of the consequences of miR-193b overexpression on recovery of KYSE450 oesophageal cancer cells. a KYSE450 cells were
transfected with miR-193b mimic or negative control mimic (5 nM) and were assessed for expression of stathmin 1 (miR-193b target) by western
blotting at 48 and 72 h post-transfection. β-actin was used as a loading control. Stathmin 1 levels were normalised to actin and quantification is
shown in the lower panel. Data is presented as mean +/- S.E.M (n = 2). KYSE450 cells were transfected with miR-193b mimic or negative control
(5 nM) and 24 h later were treated with 5-FU (10 μM or 30 μM) for 24 (b) and 48 (c) hours. Drug-treated and control cells were counted and 1500
KYSE450 cells were re-seeded in triplicate wells without drug and allowed to grow for 12 days. Colonies were fixed and counted using the Odyssey
Infrared Imaging System (Li-Cor). (C ii) The number of colonies observed for negative control mimic + 30 μM 5-FU and miR-193b mimic + 30 μM 5-FU
treatments (boxed) were below the detection limit of the Odyssey Imaging system and were manually counted. Representative wells are
shown. Asterisks indicate statistical significance determined by t-test (**p < 0.01, ***p < 0.001)
Fig. 3 Evaluation of the consequences of Stathmin 1 knockdown on recovery of KYSE450 oesophageal cancer cells. a KYSE450 cells were transfected with
stathmin 1 siRNA or scrambled siRNA (20 nM) and stathmin 1 levels were assessed by western blotting at 24, 48 and 72 h post-transfection. β-actin was
used as a loading control. Stathmin 1 levels were normalised to actin and quantification is shown in the lower panel. Data is presented as mean +/- S.E.M
(n= 2), (the 24 h time point is not a duplicate. However, 48 and 72 h transfection time points correspond to 24 and 48 h time points in the clonogenic
assays below). b KYSE450 cells were transfected with stathmin 1 siRNA or scrambled siRNA (20 nM) and 24 h later were treated with 5-FU (10 μM or
30 μM) for 48 h. Drug-treated and control cells were counted and 1500 KYSE450 cells were re-seeded in triplicate wells without drug and allowed to grow
for 12 days. Colonies were fixed and counted using the Odyssey Infrared Imaging System. Representative wells are shown. Asterisks indicate statistical
significance determined by t-test (*p< 0.05, ***p< 0.001)
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Fig. 4 (See legend on next page.)
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control mimic treated cells (Fig. 4b – lower right panel,
indicated by arrows). Apoptosis was rarely observed, in
keeping with the caspase 3 data. Similar results were
seen with 30 μM 5-FU treatment (data not shown).
The vesicular morphology observed suggested that au-
tophagy may be induced following miR-193b overexpres-
sion or with 5-FU treatment. Autophagy vesicles were
quantified using the Cyto-ID reagent, which specifically
fluoresces in autophagic vesicles. Untransfected (shaded
histogram) and negative control transfected cells (red
overlay) had equivalent levels of fluorescence (Fig. 4c (i);
and graphed to the right). KYSE450 cells ectopically
expressing miR-193b for 48 h (Fig. 4c (i); blue overlay)
showed increased levels of Cyto-ID fluorescence (**p =
0.0018). Autophagy was also assessed in cells treated
with 5-FU (10 μM) for 24 h. Cells transfected with the
miR-193b mimic and 5-FU showed significantly higher
levels of autophagy compared to the negative control
mimic transfected cells treated with 5-FU (*p = 0.0102)
(Fig. 4c (ii); pink overlay compared to green). Similar
results were seen with 30 μM 5-FU (data not shown).
MiR-193b overexpression affects autophagy flux
Autophagy induction following miR-193b overexpression
was further assessed by examining the levels of LC3 II
(autophagy marker). Higher levels of LC3 II expression
were observed in miR-193b overexpressing cells com-
pared to their corresponding negative control as de-
tected by western blotting (Fig. 5a). Together with the
Cyto-ID analysis, these results suggested that miR-193b
overexpression increased the levels of autophagic vesi-
cles in these cells.
We then assessed whether overexpression of miR-193b
affected “autophagic flux” in KYSE450 cells. This term is
used to incorporate all stages of the autophagy process,
including formation of the autophagosome, transport of
autophagic substrates to the lysosome and fusion and
degradation inside the lysosome [26]. To distinguish
between autophagy induction and vesicle accumulation
solely due to lack of vesicle processing, chloroquine, a
lysomotrophic agent was used to block autophagosome-
lysosome fusion. In the presence of chloroquine, the
levels of autophagosomes will not be further increased
unless more autophagy has been initiated [27]. KYSE450
cells were transfected with the miR-193b mimic or nega-
tive control mimic and 24 h later were treated with
chloroquine (10 μM) for 24 (data not shown) and 48 h
(Fig. 5b (i) & (ii)). Cyto-ID was used to assess autophagy
levels. As previously shown, untreated cells (shaded
histogram) had equivalent levels of fluorescence as cells
transfected with the negative control mimic (red over-
lay). Treatment with chloroquine alone (green overlay)
caused an increase in the levels of vesicles, consistent
with an obstruction of vesicle turnover. A further shift
in fluorescence was observed with miR-193b overexpres-
sion (blue overlay) (*p = 0.012) (Fig. 5b (i)). Graphical
representation of the mean fluorescent intensities is
shown on the right hand panel.
Chloroquine was then combined with mimics. Levels of
autophagosomes were equivalent in the negative control
mimic transfected cells plus chloroquine (black overlay) to
the levels observed in cells treated with chloroquine alone
(green overlay) (Fig. 5b (ii)) and graphed to the right). Im-
portantly, the addition of chloroquine to the miR-193b
transfected cells induced a further accumulation of autop-
hagosomes (pink overlay), beyond that observed with
either chloroquine alone (green overlay) (*p = 0.0195) or
the combination of negative mimic and chloroquine
(black overlay) (*p = 0.0277) (Fig. 5b (ii). Similar results
were also observed at 24 h (data not shown). These results
indicate that overexpression of miR-193b enhances
autophagy in the KYSE450 cells.
MiR-193b enhances chemosensitivity by inducing non-
apoptotic cell death
The significant difference observed in colony formation
assays between miR-193b mimic transfected cells treated
with 5-FU and the corresponding negative control cells
(Fig. 2b & c) could not be explained by the induction of
apoptosis at the 24 h treatment time-point (Fig. 4). There-
fore, we examined the response of cells treated for 24 h
followed by an extended incubation (96 h) in drug free
(See figure on previous page.)
Fig. 4 Examination of the effects of miR-193b overexpression on active caspase 3, cell morphology and Cyto-ID. a Active caspase 3 levels were
assessed by FACS analysis. (i) KYSE450 cells were transfected with negative control mimic or miR-193b mimic (5 nM) and the following day were
treated with 5-FU (10 μM or 30 μM) for 48 h. An upward shift in the levels of Alexa-Fluor 488 represented an increase in the number of cells with
activated caspase 3 (percentage of cells with activated caspase 3 is shown). Upper panels – negative control transfected cells treated with 10 μM
(middle) or 30 μM 5-FU (right panel). Lower panels – miR-193b transfected cells treated with 10 μM (middle) or 30 μM 5-FU (right panel). (ii) OE21
cells were treated with 30 μM 5-FU for 48 h (lower panel). b Morphological features of negative control mimic or miR-193b (5 nM) transfected
KYSE450 cells. Twenty four hours following transfection, cells were treated with 5-FU (10 μM) for 24 h and compared to untreated transfected
controls. Autophagic cells are indicated with arrows (×40 magnification). c KYSE450 cells were transfected with negative control mimic or miR-193b
mimic (5 nM). Twenty-four hours following transfection, cells were treated with 5-FU (10 μM) for 24 h and then assessed for autophagy induction using
the Cyto-ID autophagy detection assay. Representative image of FACS analysis of Cyto-ID levels of (i) untreated, negative control mimic and miR-193b
transfected cells and (ii) untreated, negative control mimic and miR-193b mimic cells treated with 10 μM 5-FU. Right hand panel - mean fluorescence
intensity of all treatments. Asterisks indicate statistical significance determined by t-test (*p < 0.05, **p < 0.01)
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media (analogous to clonogenic assays). There were
significantly more floating cells in the 5-FU treated
miR-193b transfected cells compared to the equivalent
negative control treated cells and also clear differences
in cell morphology. The predominant morphology of
5-FU treated miR-193b mimic transfected KYSE450
cells was non-apoptotic cell death (Fig. 6a – lower right
hand panel, indicated by arrowheads). In contrast, the 5-FU
Fig. 5 Evaluation of autophagy levels and flux analysis following miR-193b overexpression in KYSE450 oesophageal cancer cells. a Western blot analysis
of LC3 II (autophagy marker) expression at 48 and 72 h post-transfection with miR-193b mimic or negative control mimic (5 nM). β-actin was used as a
loading control. LC3 II levels were normalised to actin and quantification is shown in the lower panel. Data is presented as mean +/- S.E.M (n = 2). b
KYSE450 cells were transfected with negative control mimic or miR-193b mimic (5 nM). Twenty-four hours following transfection, cells were treated
with chloroquine (10 μM) and cells were assessed for autophagy induction 48 h after treatment using the Cyto-ID autophagy detection assay.
(i) Representative FACS analysis of Cyto-ID levels of untreated, chloroquine treated, negative control mimic and miR-193b transfected cells. (ii)
Representative FACS analysis of chloroquine, negative control mimic and miR-193b mimic transfected cells treated with chloroquine. The right
hand panel shows the corresponding mean fluorescence intensity of all treatments. Asterisks indicate statistical significance determined by
t-test (*p < 0.05)
Nyhan et al. BMC Cancer  (2016) 16:101 Page 9 of 13
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treated negative control mimic KYSE450 cells were healthy
with some vesicles (Fig. 6a – upper right hand panel). Simi-
lar results were seen when miR-193b was overexpressed
and treated with 5-FU for 48 h and left to recover for 96 h
(data not shown). These results suggest that miR-193b
overexpression promotes a delayed non-apoptotic cell
death in response to 5-FU treatment and this may account
for its impact on clonogenic survival.
Quantitation of autophagy vesicles by Cyto-ID analysis
was also assessed in KYSE450 cells transfected with the
miR-193b mimic, then treated with 5-FU for 24 h and
left to recover in drug free media for 96 h. As previously
shown (Fig. 4c), there was a forward shift in fluorescence
for KYSE450 cells transfected with the miR-193b com-
pared to the negative control cells. This increase in
fluorescence for miR-193b transfected cells (blue bar)
compared to negative control mimic cells was still
evident at the 96 h recovery time point (*p = 0.0115)
(Fig. 6b (i) & (ii)). This 96 h recovery data shows that
when combined with 5-FU, there were significantly
higher levels of autophagy in the miR-193b transfected
cells compared to negative control mimic cells (***p =
0.0008 and **p = 0.0039 for 10 and 30 μM 5-FU re-
spectively) (Fig. 6b (i) & (ii)). This data suggested that
co-incident with loss of viability, miR-193b transfected
cells have higher levels of autophagic vesicles. This may
be associated with a higher stress level in the cells (and
is unrelated to the death mechanism) or it is possible
that it is associated with the non-apoptotic cell death
observed at this time point.
Collectively, these results suggested that 5-FU treatment
of KYSE450 cells overexpressing miR-193b resulted in
higher levels of non-apoptotic cell death. To quantify this
cell death, we assessed the levels of HMGB1 release.
HMGB1 release is a well-known marker of various forms
of cell death including apoptosis, autophagic cell death
and necrosis in response to chemotherapy (reviewed in
[28]). We assayed levels of HMGB1 release from KYSE450
cells ectopically expressing miR-193b or the negative
control mimic, treated with 5-FU for 24 h and left to
recover in drug free media for 96 h. At the 96 h recovery
time-point, HMGB1 levels were at least three times higher
in miR-193b overexpressing cells or miR-193b overex-
pressing cells which had been treated with 5-FU compared
to the equivalent negative control cells (Fig. 6c). There-
fore, overexpression of miR-193b caused a delayed release
of HMGB1, which is normally associated with cell death.
Discussion
In this study, we have shown that expression of miR-193b
increases the chemosensitivity of oesophageal cancer cells.
Our results suggest that miR-193b may affect chemosensi-
tivity, in part, by decreasing the expression of stathmin 1.
Overexpression of miR-193b results in the induction of au-
tophagy. Heightened levels of autophagy may be important
for some of the functional activities of miR-193b or it may
be an indirect consequence of its activity.
To date, several miRNAs including miR-141, miR-200c,
miR-148a, miR-296, miR-27a, miR-483 and miR-214 have
been identified to play a role in oesophageal cancer devel-
opment and or in determining the responsiveness of these
cancer cells to chemotherapeutics [29–31]. Our data sug-
gests that miR-193b can now be added to this list of miR-
NAs whose expression affects the sensitivity of oesophageal
cancer cells to chemotherapy.
MiR-193b has been postulated to be a tumour sup-
pressor in several cancers including gastric cancer due
to its lower expression in malignant tissue compared to
the corresponding normal tissue [24, 32–35]. Putative
functions identified to date for miR-193b include the
negative regulation of proliferation, cell cycle control,
migration and invasion of hepatocellular carcinoma cells
and non-small cell lung cancer cells [34, 36]. MiR-193b
has previously been linked to enhancing chemosensitiv-
ity. In melanoma cells, overexpression of miR-193b
reduced Mcl-1 expression and sensitised these cells to
ABT-737 (BH3 mimetic) induced apoptosis [33]. In
hepatitis B virus associated hepatocellular carcinoma
cells, enhancing miR-193b expression lowered the IC50
of these cells to sorafenib treatment and apoptosis was
triggered in these cells [37]. Our research is in agreement
with these studies showing the importance of miR-193b for
chemosensitivity. Recently, a study of two oesophageal
cancer cell lines (OE19 and KYSE410) identified several
(See figure on previous page.)
Fig. 6 Analysis of morphology, autophagy levels and HMGB1 release from recovering 5-FU treated miR-193b overexpressing cells. KYSE450 cells
were transfected with negative control mimic or miR-193b (5 nM). Twenty four hours following transfection, cells were treated with 5-FU (10 μM)
for 24 h, following which these cells were allowed to recover in drug free media for 96 h. a Morphological features of negative control mimic or
miR-193b transfected KYSE450 cells which had been treated with 5-FU for 24 h and left to recover 96 h. Autophagy and non-apoptotic/type II cell
death are shown by arrows and arrowheads respectively (×40 magnification). b Cyto-ID analysis of the KYSE450 cells at the 96 h recovery time-point. Upper
panel shows FACS analysis of untreated, miR-193b mimic transfected cells in the presence or absence of 5-FU (10 (i) or 30 μM (ii)) and negative control
mimic 5-FU treated cells (10 μM (i) or 30 (ii)). Negative control mimic (fluorescence levels equivalent to untreated) and 5-FU alone treated cells
(fluorescence levels equivalent to negative control mimic treated with 5-FU) were omitted from these images to aid visualisation of the other
treatments. The lower panels show corresponding mean fluorescence intensity of all treatments. (C) At the 96 h recovery time-point, media
was removed from all treated cells to assess HMGB1 levels. HMGB1 levels were quantified using a HMGB1 ELISA. Asterisks indicate statistical
significance determined by t-test (*p < 0.05, **p < 0.01, ***p < 0.001)
Nyhan et al. BMC Cancer  (2016) 16:101 Page 11 of 13
miRNAs associated with chemoresistance. In that study,
they found that OE19 cells which were engineered to be
resistant to 5-FU had higher expression levels of miR-193b
compared to their parental cells [38]. This is in contradic-
tion to our research which showed that chemosensitive
cells had higher expression levels of miR-193b. The mech-
anism of chemoresistance was not investigated in that
analysis. However, our work is the first reported study
showing that miR-193b overexpression in combination with
5-FU treatment results in the induction of autophagy and
non-apoptotic cell death. MiR-193b’s functional role has
never been previously investigated in oesophageal cancer
cells and our work indicated that overexpression of this
miRNA in combination with 5-FU treatment is effective in
sensitising these drug resistant cells.
Several reports have shown that miR-193b directly targets
Mcl-1 [33, 37]. The authors report that suppressing the
anti-apoptotic protein Mcl-1 induced apoptosis in these
cells. However, in our study, overexpression of miR-193b
did not trigger apoptosis in our cells and consequently
alternative targets of miR-193b were investigated. We
identified that miR-193b may influence chemosensitiv-
ity through the negative regulation of stathmin 1. Silen-
cing of stathmin 1 could at least partially re-capitulate
the enhanced sensitivity to 5-FU that was observed with
the overexpression of miR-193b. MiR-193b has been
shown to regulate the expression of stathmin 1 and
consequently affected tumour growth and metastasis in
pancreatic cells [24]. Stathmin 1 has also been reported
to affect cell proliferation and migration capabilities of
melanoma cells [23]. Knockdown or low levels of stath-
min 1 could sensitise breast cancer cells to paclitaxel,
vinblastine or docetaxel respectively demonstrating its
importance in determining the responsiveness of cancer
cells to chemotherapeutics [16, 18]. High expression
levels of stathmin 1 have been associated with lymph
node metastasis and increased malignancy in oesophageal
adeno and squamous cell carcinoma [39, 40]. Of note,
stathmin 1 has also been putatively identified as an au-
tophagy regulator, potentially through its importance for
microtubule dynamics [12, 41]. As miR-193b potentially
influences the expression of greater than 200 genes, it is
likely that there are additional targets of this miRNA
which may, at least in part, affect chemosensitivity.
There have been no previously reported studies linking
miR-193b and autophagy. In our study, we showed that
overexpression of miR-193b results in an increase of LC3
II and autophagic vesicles (as determined by Cyto-ID) and
also affected autophagy flux. It is unclear from this study
whether increased expression of miR-193b directly or in-
directly affected autophagy. To date, there have been far
in excess of twenty miRNAs implicated directly in the
regulation of autophagy and this list is increasing rapidly
[11–14]. The impact of de-regulation of these miRNAs on
autophagy and on cellular processes including cell death is
only beginning to emerge. Further analysis could add
miR-193b to this list. For example, miR-23b has been
shown to directly target ATG12b. Overexpression of this
miRNA sensitised pancreatic cells to radiotherapy by inhi-
biting radiation induced autophagy. The mechanism
which resulted in the reduced survivability of these cells
was not delineated [42]. In melanoma cells, miR-290-295
cluster suppressed autophagic cell death in response to
glucose starvation through the down-regulation of ATG7
and ULK1 [43].
In our study, it is possible that miR-193b’s relationship
with stathmin 1 (potential autophagy regulator) may be
important for the autophagy induction observed following
miR-193b overexpression. However, it remains a possibility
that miR-193b increases the autophagy level in these cells
through an indirect mechanism. For example, we could
postulate that enhanced miR-193b expression could elevate
accumulation of macro-molecular structures or organelles
(e.g. through effects on microtubules) and consequently
induces autophagy (indirect mechanism). The exact rela-
tionship between miR-193b and autophagy remains to be
fully elucidated.
Conclusions
MiR-193b is a regulator of chemosensitivity, potentially
through the regulation of autophagy. The enhanced cell
death associated with miR-193b overexpression suggests
that this novel miRNA has a potential application in
oesophageal cancer therapy.
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